Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Blood (2023) 142 (Supplement 1): 826.

https://doi.org/10.1182/blood-2023-174973

Published: 2023

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 6119–6121.

https://doi.org/10.1182/blood-2022-157937

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Myeloma Lytic Bone Lesions Characterization with WB-LDCT and 18 f-FDG PET/MRI

Albana Lico, MD, Gregorio Barilà, MD, Filippo Crimì, MD, Lucia Checuz, MD, Tamara Berno, MD, Stefania Vio, MD, Antonio Branca, MD, Lucia Ammirati, MD, Matteo Leoncin, MD, Pietro Zucchetta, MD, Carmelo Lacognata, MD, Francesco Piazza, MD, Gianpietro Semenzato, MD, Renato Zambello, MD

Blood (2017) 130 (Supplement 1): 1788.

https://doi.org/10.1182/blood.V130.Suppl_1.1788.1788

Published: 2017

Journal Articles

Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells

Barila' Gregorio, MD, Antonella Teramo, PhD, Giulia Calabretto, BS, Chiara Ercolin, BS, Albana Lico, MD, Antonio Branca, MD, Tamara Berno, MD, Anna Cabrelle, BS, Elisa Boscaro, BS, Monica Facco, MS, Livio Trentin, MD, Francesco Piazza, MD, Gianpietro Semenzato, Renato Zambello

Blood (2015) 126 (23): 3876.

https://doi.org/10.1182/blood.V126.23.3876.3876

Published: 2015

Journal Articles

Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia

Antonella Teramo, Cristina Gattazzo, Francesca Passeri, Albana Lico, Giulia Tasca, Anna Cabrelle, Veronica Martini, Federica Frezzato, Valentina Trimarco, Elisa Ave, Elisa Boscaro, Francesco Piazza, Monica Facco, Livio Trentin, Gianpietro Semenzato, Renato Zambello

Blood (2013) 121 (19): 3843–3854.

https://doi.org/10.1182/blood-2012-07-441378

Published: 2013

Includes: Supplemental data

Journal Articles

Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia

Renato Zambello, Antonella Teramo, Cristina Gattazzo, Francesca Passeri, Albana Lico, Giulia Tasca, Anna Cabrelle, Federica Frezzato, Veronica Martini, Valentina Trimarco, Tamara Berno, Elisa Boscaro, Monica Facco, Livio Trentin, Gianpietro Semenzato, MD

Blood (2011) 118 (21): 1375.

https://doi.org/10.1182/blood.V118.21.1375.1375

Published: 2011

NARROW

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Myeloma Lytic Bone Lesions Characterization with WB-LDCT and 18 f-FDG PET/MRI

Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells

Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia

Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only